http://www.pharmexec.com/pharmexec/PharmExec+Direct/Article/list/10312 The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2013-05-19T05:50:17Z http://www.pharmexec.com/pharmexec/Web+Exclusives/Pharma-Trials-Heading-South/ArticleStandard/Article/detail/599031?contextCategoryId=10312&ref=25 Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials. 2009-05-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212009/599031null HTML http://www.pharmexec.com/pharmexec/News+Analysis/No-Such-Thing-as-Free-Drugs/ArticleStandard/Article/detail/599072?contextCategoryId=10312&ref=25 New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.? 2009-05-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212009/599072null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Wrangling-Over-Research-Results/ArticleStandard/Article/detail/599042?contextCategoryId=10312&ref=25 Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion. 2009-05-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212009/599042null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/A-Review-of-iTafas-v-Dolli/ArticleStandard/Article/detail/599039?contextCategoryId=10312&ref=25 Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules. 2009-05-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212009/599039null HTML http://www.pharmexec.com/pharmexec/Sales/New-Study-Reveals-Distribution-Trends-in-Drug-Samp/ArticleStandard/Article/detail/482397?contextCategoryId=10312&ref=25 Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees. 2008-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/482397null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Data-Mining-Companies-Score-Legal-Win-in-Maine/ArticleStandard/Article/detail/482387?contextCategoryId=10312&ref=25 IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms. 2008-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/482387null HTML http://www.pharmexec.com/pharmexec/R%26D/BioMS-Medical-Signs-500-Million-Agreement-with-Lil/ArticleStandard/Article/detail/482390?contextCategoryId=10312&ref=25 Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. 2008-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/482390null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Preemption-Gets-Boost-from-Bush/ArticleStandard/Article/detail/478463?contextCategoryId=10312&ref=25 State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer? 2007-12-12T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502007/478463null HTML http://www.pharmexec.com/pharmexec/News+Analysis/BMS-Cuts-Bloated-Manufacturing-Arm-to-Bolster-Ramp/ArticleStandard/Article/detail/478464?contextCategoryId=10312&ref=25 Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing. 2007-12-12T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502007/478464null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Duke-Partners-with-FDA-to-Modernize-Clinical-Trial/ArticleStandard/Article/detail/475929?contextCategoryId=10312&ref=25 In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient. 2007-11-29T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/475929null HTML http://www.pharmexec.com/pharmexec/News+Analysis/FDA-Recommends-Precautionary-Warnings-for-This-Sea/ArticleStandard/Article/detail/475936?contextCategoryId=10312&ref=25 An FDA review team advised that flu vaccines manufactured by GSK and Roche include precautionary warnings citing the potential for neuropsychiatric side effects. Adverse events have been reported in Japan, and now the United States is starting to pay attention. 2007-11-29T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/475936null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Chantix-Concerns-Prompt-FDA-Investigation/ArticleStandard/Article/detail/475931?contextCategoryId=10312&ref=25 Side effects associated with Pfizer?s smoking-cessation drug have caused a stir in the blogosphere, prompting FDA to seek further information about incidents of depression and suicidal thoughts. 2007-11-29T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/475931null HTML http://www.pharmexec.com/pharmexec/News+Analysis/No-Gains-for-Women-in-Pharma/ArticleStandard/Article/detail/472512?contextCategoryId=10312&ref=25 Despite more programs to increase diversity, a new study shows that women are gaining no ground in climbing pharma's corporate ladder. 2007-11-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462007/472512null HTML http://www.pharmexec.com/pharmexec/News+Analysis/JampJ-vs-Red-Cross-The-Battle-Continues/ArticleStandard/Article/detail/472527?contextCategoryId=10312&ref=25 Court rejects one of J&J's eight claims, but trademark dispute case will proceed. 2007-11-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462007/472527null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Is-Mercks-Long-Vioxx-Nightmare-Really-Over/ArticleStandard/Article/detail/472514?contextCategoryId=10312&ref=25 A prominent pharma litigator argues that Merck's settlement was predictable from the start. And it has a chance of success—provided that it survives a key legal challenge and can meet its mark with plaintiff sign-on. 2007-11-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462007/472514null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Tightens-Its-Belt/ArticleStandard/Article/detail/469007?contextCategoryId=10312&ref=25 GSK to shutter plants and move some manufacturing overseas in hopes of offsetting money lost to the sharp decline in Avandia sales. 2007-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469007null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Genzyme-Forms-Partnership-with-Overseas-Gene-Thera/ArticleStandard/Article/detail/469010?contextCategoryId=10312&ref=25 Genzyme will collaborate with Chinese biotech manufacturer Sunway to perform clinical trials and potentially produce the experimental gene therapy HIF-1a in China. 2007-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469010null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Eli-Lilly-Quietly-Suspends-Two-Trials/ArticleStandard/Article/detail/469014?contextCategoryId=10312&ref=25 The company halts two small pharmacodynamic trials of a key candidate just days before a major presentation of data. Is something wrong with prasugrel? And why is Lilly playing the news so close to the chest? 2007-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469014null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Medtronic-Wins-Recommendation-for-Safer-Drug-Eluti/ArticleStandard/Article/detail/465613?contextCategoryId=10312&ref=25 FDA advisory panel notes high efficacy—and no thrombosis after six months—in clinical trials. Nonetheless, Medtronic's stents will be under close postapproval watch. 2007-10-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422007/465613null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Moodys-Drops-Credit-Rating-of-Pharma-Industry/ArticleStandard/Article/detail/465607?contextCategoryId=10312&ref=25 The industry drops in a major ranking from stable to negative. The reasons: patent expirations, slow drug approvals, and likelihood of cash-draining acquisitions. 2007-10-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422007/465607null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-to-Pay-1-Billion-for-Synta-Melanoma-Drug/ArticleStandard/Article/detail/465605?contextCategoryId=10312&ref=25 In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug. 2007-10-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422007/465605null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Big-Pharma-Forms-Consortium-for-Drug-Safety/ArticleStandard/Article/detail/461949?contextCategoryId=10312&ref=25 Introducing the International Serious Adverse Events Consortium, a new industry group that wants to identify the molecular roots of serious drug reactions. SAEC's first targets: liver failure and serious skin rashes. 2007-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/461949null HTML http://www.pharmexec.com/pharmexec/News+Analysis/FDA-Switches-Up-Senior-Staff/ArticleStandard/Article/detail/461950?contextCategoryId=10312&ref=25 Galson and Woodcock were named acting surgeon general and director of CDER, respectively. Industry vets weigh in on the appointments. 2007-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/461950null HTML http://www.pharmexec.com/pharmexec/News+Analysis/BMS-Snags-Biotech-Firm-Adnexus/ArticleStandard/Article/detail/461948?contextCategoryId=10312&ref=25 Adnexus' protein-building technology could spell new drugs and big profits for BMS--if the drug development engine works. 2007-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/461948null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Boosts-Flu-Doses/ArticleStandard/Article/detail/458135?contextCategoryId=10312&ref=25 Drug company increases vaccine supply by 10 million in advance of influenza season 2007-09-19T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382007/458135null HTML http://www.pharmexec.com/pharmexec/PharmExec+Direct/House-Passes-Patent-Reform-Legislation/ArticleStandard/Article/detail/458136?contextCategoryId=10312&ref=25 Patent overhaul could cramp pharma industry?s style 2007-09-19T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382007/458136null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Cephalon-Issues-Dear-Doctor-Letter-for-Fentora/ArticleStandard/Article/detail/458144?contextCategoryId=10312&ref=25 Drugmaker updates information on the use and side effects of cancer pain medication 2007-09-19T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382007/458144null HTML http://www.pharmexec.com/pharmexec/News+Analysis/New-Rules-for-Asthma-Med-Makers/ArticleStandard/Article/detail/454640?contextCategoryId=10312&ref=25 NHLBI releases updated regulations for asthma treatment 2007-09-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362007/454640null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Round-One-to-Amgen-in-Epo-Patent-Face-Off/ArticleStandard/Article/detail/454603?contextCategoryId=10312&ref=25 The biotech, bruised and battered, comes up with a win against Roche 2007-09-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362007/454603null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Data-Clamp-Down/ArticleStandard/Article/detail/454637?contextCategoryId=10312&ref=25 Data-collection companies sue for freedom to gather information 2007-09-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362007/454637null HTML